Dataset for the proteomic inventory and quantitative analysis of the breast cancer hypoxic secretome associated with osteotropism

Data in Brief

Volumn 5, Issue , 2015, Pages 621-625

  Cox, Thomas R ^a   Schoof, Erwin M ^b,d   Gartland, Alison ^c   Erler, Janine T ^a   Linding, Rune ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Bone metastasis; Breast cancer; Hypoxia; Lysyl Oxidase; Pre metastatic Niche; Proteomics; Secretome

Indexed keywords

CYTOLOGY; DISEASES; MASS SPECTROMETRY; MOLECULAR BIOLOGY; PROTEINS;

BONE METASTASIS; BREAST CANCER; CANCER CELLS; HOST CELLS; HYPOXIA; LYSYL OXIDASE; MICROENVIRONMENTS; PRE-METASTATIC NICHE; PROTEOMICS; SECRETOME;

CELLS;

EID: 84946407876     PISSN: None     EISSN: 23523409     Source Type: Journal    
DOI: 10.1016/j.dib.2015.09.039     Document Type: DP

References (5)

1. Cox T.R., et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 2015, 522(7554):106-110.
2. Vizcaino J.A., et al. The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2013, 41(Database issue):D1063-D1069.
3. Kang Y., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3(6):537-549.
4. Rappsilber J., Mann M., Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2007, 2(8):1896-1906.
5. Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26(12):1367-1372.